IP Library Granted Patent US 12,473,556
Granted Patent B2
US 12,473,556 · App. 17/159,797 · Granted Nov 18, 2025

Methods for stabilizing production of acetyl-coenzyme a derived compounds

Inventors: Hanxiao Jiang (Emeryville, CA); Adam Meadows (Emeryville, CA)
Assignees: AMYRIS, INC.; TOTAL MARKETING SERVICES
C12N15/52C12N1/20C12N9/1085C12N9/88C12N9/90C12N15/635C12P5/007C12Y205/01C12Y402/03047C12Y503/03002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,473,556
App. No.
17/159,797
Granted
Nov 18, 2025
Kind
B2
Abstract

The present disclosure relates to the use of a switch for the production of heterologous non-catabolic compounds in microbial host cells. In one aspect, provided herein are genetically modified microorganisms that produce non-catabolic compounds more stably when serially cultured under aerobic conditions followed by microaerobic conditions, and methods of producing non-catabolic compounds by culturing the genetically modified microbes under such culture conditions. In another aspect, provided herein are genetically modified microorganisms that produce non-catabolic compounds more stably when serially cultured in the presence of maltose followed by the reduction or absence of maltose, and methods of producing non-catabolic compounds by culturing the genetically modified microbes under such culture conditions.

Claims (19)

1 . A fermentation composition comprising a population of genetically modified host cells in a culture medium comprising a carbon source, wherein the host cells comprise:

one or more heterologous nucleic acids encoding one or more enzymes of an enzymatic pathway for making the heterologous non-catabolic compound; and

a microaerobic-responsive promoter operably linked to a heterologous nucleic acid encoding a transcriptional regulator that positively regulates the expression of the one or more heterologous nucleic acids encoding the one or more enzymes of the enzymatic pathway, wherein expression of the transcriptional regulator is increased under microaerobic conditions, and wherein the microaerobic-responsive promoter is operably linked to a heterologous nucleic acid encoding a transcriptional regulator that positively regulates the expression of the one or more heterologous nucleic acids encoding one or more enzymes of the enzymatic pathway, and wherein expression of the transcriptional regulator is increased under microaerobic fermentation conditions.

2 . The fermentation composition of claim 1 , wherein the transcriptional regulator is Gal4p, and the one or more heterologous nucleic acids encoding the one or more enzymes of the enzymatic pathway are each operably linked to a Gal4p-responsive promoter selected from the group consisting of pGAL1, pGAL7 and pGAL10.

3 . The fermentation composition of claim 1 , wherein the microaerobic-responsive promoter is a mutated DAN1 promoter selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10.

4 . The fermentation composition of claim 3 , wherein the mutated DAN1 promoter sequence comprises SEQ ID NO:1.

5 . The fermentation composition of claim 3 , wherein the mutated DAN1 promoter sequence comprises SEQ ID NO:2.

6 . The fermentation composition of claim 1 , wherein the culture medium comprises a dissolved oxygen concentration of 100%.

7 . The fermentation composition of claim 1 , wherein the culture medium comprises a dissolved oxygen concentration of less than about 20%, less than about 15%, less than about 10%, or less than about 5%.

8 . The fermentation composition of claim 1 wherein the culture medium comprises a dissolved oxygen concentration of about 0%.

9 . The fermentation composition of claim 1 , wherein the oxygen uptake rate of the host cells is less than about 50 mmoles, less than about 40 mmoles, less than about 30 mmoles, less than about 20 mmoles per liter of medium, or less than about 10 mmoles per liter of medium per hour.

10 . The fermentation composition of claim 1 , wherein the specific oxygen uptake rate of the host cells is less than about 30 mmoles, less than about 25 mmoles, less than about 20 mmoles, less than about 15 mmoles, less than about 10 mmoles, or less than about 5 mmoles per gram of dry cell weight per hour.

11 . A fermentation composition comprising a population of genetically modified host cells in a culture medium comprising a carbon source, wherein the host cells comprise:

(a) one or more heterologous nucleic acids encoding one or more enzymes of a mevalonate (MEV) pathway, each operably linked to a Gal4p-responsive promoter; and

(b) a nucleic acid encoding Gal4p, operably linked to a microaerobic-responsive promoter, wherein the microaerobic-responsive promoter limits the amount of a heterologous isoprenoid produced by the host cells in aerobic conditions, and wherein microaerobic conditions increase the production of a heterologous isoprenoid by the host cells.

12 . The fermentation composition of claim 11 , wherein the host cells further comprise a functional disruption of Gal80p.

13 . A fermentation composition comprising a population of genetically modified host cells in a culture medium comprising a carbon source, wherein the host cells comprise:

(a) one or more heterologous nucleic acids encoding one or more enzymes of a mevalonate (MEV) pathway, each operably linked to a Gal4p-responsive promoter; and

(b) a nucleic acid encoding Gal4p, operably linked to a microaerobic-responsive promoter, wherein the microaerobic-responsive promoter is a DAN1 promoter selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10, and wherein the microaerobic-responsive promoter limits the amount of a heterologous isoprenoid produced by the host cells in aerobic conditions, and wherein the microaerobic-responsive promoter increases the production of a heterologous isoprenoid by the host cells in microaerobic conditions.

Assignments (9)
SECURITY INTEREST Recorded Jan 9, 2026
From: AMYRIS, INC.
To: EUAGORE, LLC
Reel/Frame 073419/0255 →
SECURITY INTEREST Recorded May 24, 2024
From: AMYRIS, INC.
To: EUAGORE, LLC
Reel/Frame 067528/0467 →
SECURITY INTEREST Recorded Aug 17, 2023
From: AMYRIS, INC.; AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; APRINNOVA, LLC; AMYRIS-OLINKA, LLC; ONDA BEAUTY INC.; UPLAND 1 LLC; AMYRIS ECO-FAB LLC; CLEAN BEAUTY 4U HOLDINGS, LLC; AMYRIS CLEAN BEAUTY LATAM LTDA; INTERFACES INDUSTRIA E COMERCIA DE COSMETICOS LTDA; AMYRIS BIOTECHNOLOGIA DO BRASIL LTDA; AMYRIS EUROPE TRADING B.V. (NETHERLANDS); AMYRIS BIO PRODCUTS PORTUGAL, UNIPESSOAL, LDA; BEAUTY LABS INTERNATIONAL LIMITED; AMYRIS UK TRADING LIMITED
To: EUAGORE, LLC
Reel/Frame 064619/0778 →
SECURITY INTEREST Recorded Aug 3, 2023
From: AMYRIS CLEAN BEAUTY, INC.; AMYRIS FUELS, LLC; AB TECHNOLOGIES LLC; AMYRIS, INC.
To: MUIRISC, LLC
Reel/Frame 064492/0518 →
RELEASE OF SECURITY INTEREST Recorded Jan 6, 2023
From: NAXYRIS S.A.
To: AMYRIS, INC.
Reel/Frame 062310/0378 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2022
From: AMYRIS, INC.
To: TOTAL MARKETING SERVICES
Reel/Frame 061774/0667 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 11, 2022
From: JIANG, HANXIAO; MEADOWS, ADAM
To: AMYRIS, INC.
Reel/Frame 061732/0364 →
SECURITY INTEREST Recorded Oct 18, 2022
From: AMYRIS, INC.
To: FORIS VENTURES, LLC
Reel/Frame 061703/0499 →
SECURITY INTEREST Recorded Jun 3, 2021
From: AMYRIS, INC., AS IP GRANTOR; AMYRIS BIO PRODUCTS PORTUGAL, UNIPESSOAL, LDA, AS IP GRANTOR
To: NAXYRIS S.A., AS LENDER
Reel/Frame 056427/0091 →
Continuity (3)
Division 14419609
Provisional Application 61680687 · Aug 7, 2012
Related Publication 20210155939A1 · May 27, 2021
References Cited (27)
US 6271359B1 · Norris et al. · 2001 [cited by applicant]
US 20030166204A1 · Croteau et al. · 2003 [cited by applicant]
US 20040072323A1 · Matsuda et al. · 2004 [cited by applicant]
US 20040170970A1 · Varshavsky et al. · 2004 [cited by applicant]
US 20060234334A1 · Cheng et al. · 2006 [cited by applicant]
US 20070178505A1 · Fischer et al. · 2007 [cited by applicant]
US 20080281135A1 · Tissier et al. · 2008 [cited by applicant]
US 20090053797A1 · Shiba · 2009 [cited by examiner]
US 20090269801A1 · Gardner et al. · 2009 [cited by applicant]
US 20100055754A1 · Pitera et al. · 2010 [cited by applicant]
US 20100311065A1 · Ubersax · 2010 [cited by examiner]
US 20110091952A1 · Sherman et al. · 2011 [cited by applicant]
US 20120276587A1 · Beck et al. · 2012 [cited by applicant]
Nevoigt, Progress in metabolic engineering of [cited by examiner]
Nevoight, Engineering promoter regulation, Biotechnol. Bioeng. 96, 2007, 550-58. (Year: 2007). [cited by examiner]
Rieger et al., Chapter 56: The respiratory capacity of [cited by examiner]
Johnston, A model fungal gene regulatory mechanism, Microbiol. Rev. 51, 1987, 458-76. (Year: 1987). [cited by examiner]
Farhi et al, Harnessing yeast subcellular compartments for the production of plant terpenoids, Metabolic Eng. 13, 2011, 474-481. (Year: 2011). [cited by examiner]
Genbank, Accession No. CP009954, 2015, www.ncbi.nlm.nih.gov. (Year: 2015). [cited by examiner]
Uniprot, Accession No. P47178, 2025, www.uniprot.org. (Year: 2025). [cited by examiner]
Xie e al., Construction of a Controllable b-Carotene Biosynthetic Pathway by Decentralized Assembly Strategy in [cited by examiner]
Han et al. “Characterization of an Oxygen-Dependent Inducible Promoter, the [cited by applicant]
International Search Report and Written Opinion in PCT/US2013/054030, mailed Oct. 4, 2013, 13 pages. [cited by applicant]
Carrau et al., “De novo synthesis of monoterpenes by [cited by applicant]
Ostergaard et al., “Increasing galactose consumption by [cited by applicant]
Okamura et al., “Unprecedented acetoacetyl-coenzyme A synthesizing enzyme of the thiolase superfamily involved the mevlonate pathway”, Proc. Natl. Acad. Sci., vol. 107, No. 25, 2010, pp. 11265-11270. [cited by applicant]
SEQ Align-1, 2017, pp. 1-2. [cited by applicant]